Agency for Health Care Policy and Research
Sickle cell disease: screening, diagnosis, management, and counseling in newborns and infants. The Agency for Health Care Policy and Research
Abstract
The AHCPR guideline on sickle cell disease has several strengths and many weaknesses. For the practicing physician it is strongest in recommending medical management of infants with sickle cell disease but weakest on screening and education and counseling. The evidence-based methodology should have been presented in more detail. Until that occurs, family physicians are left with this guideline as a summary of expert opinions with variable documentation of the underlying science.
Source and rights
Published by The Journal of the American Board of Family Practice, 1994. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- Agency for Health Care Policy and Research
- Published
- 1994
- Applies to
- 🇺🇸 United States
- Scope
- National
- Journal
- The Journal of the American Board of Family Practice
- PubMed
- 8184704
- Added to Prognia
- 24 July 2026
More in haematology
- Perceived relative clinical significance of the risks of venous thromboembolism and bleeding from pharmacologic thromboprophylaxis in children: an international survey of pediatric providers: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisInternational Society on Thrombosis and Haemostasis · 2026
- Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerInfectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) · 2026
